These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 19041364)
1. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Russell-Jones D Mol Cell Endocrinol; 2009 Jan; 297(1-2):137-40. PubMed ID: 19041364 [TBL] [Abstract][Full Text] [Related]
2. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Montanya E; Sesti G Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994 [TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide. Watson E; Jonker DM; Jacobsen LV; Ingwersen SH J Clin Pharmacol; 2010 Aug; 50(8):886-94. PubMed ID: 20133507 [TBL] [Abstract][Full Text] [Related]
4. Clinical studies of liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus. Drab SR Pharmacotherapy; 2009 Dec; 29(12 Pt 2):43S-54S. PubMed ID: 19947816 [TBL] [Abstract][Full Text] [Related]
5. Liraglutide: a review of the first once-daily GLP-1 receptor agonist. Bode B Am J Manag Care; 2011 Mar; 17(2 Suppl):S59-70. PubMed ID: 21517658 [TBL] [Abstract][Full Text] [Related]
7. Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Davies MJ; Kela R; Khunti K Diabetes Obes Metab; 2011 Mar; 13(3):207-20. PubMed ID: 21205109 [TBL] [Abstract][Full Text] [Related]
9. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Vilsbøll T Expert Opin Investig Drugs; 2007 Feb; 16(2):231-7. PubMed ID: 17243943 [TBL] [Abstract][Full Text] [Related]
10. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Flint A; Kapitza C; Hindsberger C; Zdravkovic M Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of liraglutide, a long-acting, potent glucagon-like peptide-1 analog. Meece J Pharmacotherapy; 2009 Dec; 29(12 Pt 2):33S-42S. PubMed ID: 19947815 [TBL] [Abstract][Full Text] [Related]
12. Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes. Ryan GJ; Hardy Y J Clin Pharm Ther; 2011 Jun; 36(3):260-74. PubMed ID: 21545609 [TBL] [Abstract][Full Text] [Related]
13. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Malm-Erjefält M; Bjørnsdottir I; Vanggaard J; Helleberg H; Larsen U; Oosterhuis B; van Lier JJ; Zdravkovic M; Olsen AK Drug Metab Dispos; 2010 Nov; 38(11):1944-53. PubMed ID: 20709939 [TBL] [Abstract][Full Text] [Related]
14. Liraglutide in type 2 diabetes: from pharmacological development to clinical practice. Rossi MC; Nicolucci A Acta Biomed; 2009 Aug; 80(2):93-101. PubMed ID: 19848045 [TBL] [Abstract][Full Text] [Related]
15. An overview of the pharmacokinetics, efficacy and safety of liraglutide. Bode B Diabetes Res Clin Pract; 2012 Jul; 97(1):27-42. PubMed ID: 22245694 [TBL] [Abstract][Full Text] [Related]
16. The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen. Kapitza C; Zdravkovic M; Hindsberger C; Flint A Adv Ther; 2011 Aug; 28(8):650-60. PubMed ID: 21792552 [TBL] [Abstract][Full Text] [Related]